Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk.

Authors:
Paraskevis D; Gkova M; Mellou K; Gerolymatos G; Psalida N and 14 more

Journal:
J Infect Dis

Publication Year: 2023

DOI:
10.1093/infdis/jiad324

PMCID:
PMC10733724

PMID:
37565522

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Infect Dis

Abbreviation: J Infect Dis

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Communicable Diseases

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Accumulation of Immunity in Heavy-Tailed Sexual Contact Networks Shapes Mpox Outbreak Sizes.
Murayama H; Pearson CAB; Abbott S and 5 more (2024) - Transparency Score: 4/6
A Phase 2 Extension Study Evaluating the Immunogenicity, Safety, and Tolerability of 3 or 4 Doses o…
Remich S; Kitchin N; Peterson J and 8 more (2024) - Transparency Score: 4/6
COVID-19 Recovery: Consistent Absence of Cerebrospinal Fluid Biomarker Abnormalities in Patients Wi…
Kanberg N; Grahn A; Stentoft E and 19 more (2024) - Transparency Score: 3/6
Diverging Maternal and Cord Antibody Functions From SARS-CoV-2 Infection and Vaccination in Pregnan…
Adhikari EH; Lu P; Kang YJ and 7 more (2024) - Transparency Score: 3/6
Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resista…
Chou S; Alain S; Cervera C and 9 more (2024) - Transparency Score: 4/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Potential conflicts of interest. All authors: No reported conflicts.: All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed."

Evidence found in paper:

"Financial support. The publication cost was supported by the National Public Health Organization, Greece. Financial support ."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025